Posted by Michael Wonder on 16 Dec 2015
Kadcyla price too high for routine NHS funding, says NICE in final guidance
16 December 2015 - NICE has issued its final guidance on the use of Kadcyla (trastuzumab emtansine) as a treatment for a type of advanced breast cancer.
For more details, go to: http://www.nice.org.uk/news/press-and-media/kadcyla-price-too-high-for-routine-nhs-funding-says-nice-in-final-guidance
